<SEC-DOCUMENT>0001279569-18-000143.txt : 20180126
<SEC-HEADER>0001279569-18-000143.hdr.sgml : 20180126
<ACCEPTANCE-DATETIME>20180126090838
ACCESSION NUMBER:		0001279569-18-000143
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180125
FILED AS OF DATE:		20180126
DATE AS OF CHANGE:		20180126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		18549976

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of January 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">News Release Dated January 25, 2018: ESSA Announces
        Management Team Change</A></FONT></P>


</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    January 25, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JANUARY 25, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><IMG SRC="image_001.jpg" ALT="ESSA Logo (CNW Group|ESSA Pharma Inc)" STYLE="height: 69px; width: 184px"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA Announces Management Team Change</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, Jan. 25, 2018 /CNW/ - ESSA Pharma Inc.
(TSXV: EPI; Nasdaq: EPIX) (&quot;<B>ESSA</B>&quot; or the &quot;<B>Company</B>&quot;) announced today that &nbsp;Frank Perabo,
M.D., Ph.D., will depart ESSA as the Company's Chief Medical Officer to pursue other opportunities, effective January 31, 2018.&nbsp;
Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA's medical advisory committee.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">ESSA announced in September 2017, its intention to cease clinical
development of EPI-506 and&nbsp; utilize the results from the successfully completed Phase 1 proof of concept trial to expand the
preclinical development program around more potent next-generation aniten molecules.&nbsp; Within the next-generation program,
the Company expects to file an Investigational New Drug filing and initiate a Phase 1 clinical trial of the selected next-generation
molecule in the first quarter of 2019.&nbsp; ESSA recently announced the completion of an approximately &nbsp;US$26 million financing
to fund preclinical and clinical development within its next-generation Aniten program.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">&quot;Frank's leadership in the successful completion of our
Phase 1 study of EPI-506 was critical in positioning us well to focus on our next-generation Aniten molecules,&quot; said&nbsp;
David Parkinson M.D., President and CEO of ESSA.&nbsp; &quot;We thank Frank for his important contributions as Chief Medical Officer,
and are delighted that he will continue to support the Company in an advisory role, and as a member of our medical advisory committee.
With the recently completed financing, ESSA now has the resources to appropriately leverage the learnings from the EPI-506 study
as we develop more potent molecules that target the N-terminal domain of the androgen receptor for the effective treatment of prostate
cancer.&quot;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The EPI series of compounds inhibit androgen receptor (&quot;<B>AR</B>&quot;)
mediated transcription by selective binding to the N-terminal domain (&quot;<B>NTD</B>&quot;) of AR.&nbsp; In preclinical studies,
these compounds inhibit AR-driven biology and have important prostate cancer activity even in the setting of resistance to the
conventional anti-androgens such as abiraterione and enzalutamide.&nbsp; In addition, non-clinical studies have documented increased
anti-tumor activity achieved by the combination of EPI compounds with anti-androgens. The Company continues to advance its development
of next generation NTD inhibitors with higher potency and enhanced pharmaceutical properties than the first generation of EPI compounds.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About ESSA Pharma Inc. </B><BR>
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castrate resistant
prostate cancer (&quot;<B>CRPC</B>&quot;) in patients whose disease is progressing despite treatment with current therapies. ESSA
believes that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can
benefit from hormone- based therapies, by disrupting the AR signaling pathway that drives prostate cancer growth and by preventing
AR transcriptional activity by binding selectively to the NTD of the AR.&nbsp; A functional NTD is essential for transactivation
of the AR. In preclinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms
of CRPC.&nbsp; ESSA was founded in 2009.&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B><BR>
<I>This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;anticipate&quot;, &quot;believe&quot;, &quot;plan&quot;, &quot;estimate&quot;, &quot;expect&quot;, and &quot;intend&quot;,
statements that an action or event &quot;may&quot;, &quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot;
be taken or occur, or other similar expressions and includes, but is not limited to, statements about Dr. Perabo's departure from
the Company as Chief Medical Officer and continuing involvement with the Company in an advisory capacity and as a member of the
Company's medical advisory committee, the acceleration of ESSA's next-generation NTD-inhibitor Aniten compounds, the anticipated
timing of the IND filing for the Aniten program and the initiation of the Phase 1 clinical trial for such program, the anticipated
sufficiency of the Company's financial resources, and the implementation of the Company's business model and strategic plans including
the advancement of the Company's development portfolio.&nbsp; &nbsp;</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which
may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby.
Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are
inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and
contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i)
the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market and economic conditions. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein, in the Company's second amended and restated prospectus supplement
dated January 5, 2018 and in ESSA's Annual Report on Form 20-F dated December 11, 2017 under the headings &quot;Risk Factors&quot;,
a copy of each which is available on ESSA's profile on the SEDAR website at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov,
and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements are made based on management's
beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking
statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable
Canadian and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><I>Neither the TSXV nor its Regulation Service Provider (as
that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/25/c1308.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 23:00e 25-JAN-18</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !# *T# 2(  A$! Q$!_\0
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H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
